127 related articles for article (PubMed ID: 10974371)
1. Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
Vella S; Galluzzo MC; Giannini G; Pirillo MF; Andreotti M; Tomino C; Fragola V; Bucciardini R; Ricciardulli D; Binelli A; Weimer LE; Floridia M
Antiviral Res; 2000 Sep; 47(3):189-98. PubMed ID: 10974371
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
3. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.
Andreoni M; Sarmati L; Ercoli L; Nicastri E; Giannini G; Galluzzo C; Pirillo MF; Vella S
AIDS Res Hum Retroviruses; 1997 May; 13(7):555-61. PubMed ID: 9135873
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
6. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
Raboud JM; Montaner JS; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg MA; Robinson P; Myers M; Hall D
AIDS; 1998 Sep; 12(13):1619-24. PubMed ID: 9764780
[TBL] [Abstract][Full Text] [Related]
7. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
[TBL] [Abstract][Full Text] [Related]
11. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
Bouscarat F; Levacher M; Landman R; Muffat-Joly M; Girard PM; Saimot AG; Brun-Vézinet F; Sinet M
AIDS; 1998 Jul; 12(11):1267-73. PubMed ID: 9708405
[TBL] [Abstract][Full Text] [Related]
12. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
13. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
[TBL] [Abstract][Full Text] [Related]
14. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
15. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM;
AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059
[TBL] [Abstract][Full Text] [Related]
16. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
17. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
Veldkamp AI; Weverling GJ; Lange JM; Montaner JS; Reiss P; Cooper DA; Vella S; Hall D; Beijnen JH; Hoetelmans RM
AIDS; 2001 Jun; 15(9):1089-95. PubMed ID: 11416710
[TBL] [Abstract][Full Text] [Related]
18. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels.
Aleman S; Visco-Comandini U; Loré K; Sönnerborg A
AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1249-54. PubMed ID: 10505673
[TBL] [Abstract][Full Text] [Related]
20. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
Sperling RS; Shapiro DE; Coombs RW; Todd JA; Herman SA; McSherry GD; O'Sullivan MJ; Van Dyke RB; Jimenez E; Rouzioux C; Flynn PM; Sullivan JL
N Engl J Med; 1996 Nov; 335(22):1621-9. PubMed ID: 8965861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
